Mata suna amfani da wannan magani don taimakawa matsananciyar zafi mai tsanani saboda yanayin da ake kira endometriosis.
Yana iya magance: Endometriosis
Brand Names: Orilissa
Class Drug: LHRH (GnRH) Masu adawa da juna
Samun: Ana buƙatar takardar sayan magani
Ciki: Ka guji amfani yayin daukar ciki
Lactation: Tuntuɓi likita kafin amfani

Elagolix wani abu ne na baka, na biyu-tsara, wanda ba peptide ba, ƙananan ƙwayoyin ƙwayoyin cuta da zaɓin hormone mai sakin gonadotropin (GnRH; LHRH) antagonist mai karɓa, tare da yuwuwar samar da aikin hanawa na hormone. Bayan gudanar da baki, elagolix yana gasa tare da GnRH don ɗaure mai karɓa kuma yana hana siginar mai karɓa na GnRH a cikin glandan pituitary na gaba. Wannan yana hana fitowar hormone luteinizing (LH) da kuma hormone mai ƙarfafa follicle (FSH). A cikin maza, hanawa na ɓoyewar LH yana hana sakin testosterone. A cikin mata, hana FSH da LH yana hana samar da estrogen daga ovaries. Hana siginar GnRH na iya magance ko hana alamun cututtukan cututtukan da suka dogara da jima'i.

Elagolix ne na baka, wanda ba na steroidal gonadotropin mai sakin hormone (GnRH) mai adawa da shi wanda ke rage yawan isrogen kuma ana amfani dashi don magance nau'i mai raɗaɗi na endometriosis a cikin mata. Maganin Elagolix yana da alaƙa da ƙarancin haɓakar haɓakar enzyme na serum yayin jiyya kuma har yanzu ba a haɗa shi da yanayin raunin hanta a asibiti ba.

An yi amfani da Elagolix a cikin gwaje-gwajen da ke nazarin ilimin kimiyya na asali da kuma maganin Endometriosis, Folliculogenesis, Uterine Fibroids, Jini Mai Girma, da Jinin Haila. Kamar yadda na 24 Yuli 2018, duk da haka, Hukumar Abinci da Magunguna ta Amurka (FDA) ta amince da AbbVie's elagolix a ƙarƙashin sunan alamar Orilissa a matsayin farkon kuma kawai na maganin gonadotropin-sakewar hormone (GnRH) antagonist musamman don mata masu matsakaici zuwa matsanancin zafi na endometriosis. An ƙaddara cewa endometriosis na ɗaya daga cikin cututtukan da aka fi sani da gynecologic a Amurka. Musamman ma, ƙididdiga sun nuna cewa ɗaya cikin goma na mata na shekarun haihuwa suna fama da endometriosis kuma suna fuskantar alamun ciwo mai lalacewa. Bugu da ƙari, matan da wannan yanayin ya shafa za su iya shan wahala har zuwa shekaru shida zuwa goma kuma su ziyarci likitoci da yawa kafin samun ganewar asali. Bayan haka, kamar yadda FDA ta amince da Orilissa (elagolix) a ƙarƙashin kulawar fifiko, wannan sabon amincewa da gaggawa yana ba ƙwararrun kiwon lafiya wani zaɓi mai mahimmanci don magance yuwuwar buƙatun matan da ke fama da cutar endometriosis, ya danganta da takamaiman nau'in su da tsananin zafin endometriosis. .

Tsarin sinadaran